Lygenesis Q3 2016 Business Update

Q3 2016 earnings update and business conference call for regenerative medicine company. Covers financial results including net loss of $3.1 million and cash position of $6.0 million, along with developments in clinical programs for implant products and tissue engineering scaffolds.